SCHEMBL5849034

SCHEMBL5849034

Cc1nn2ccccc2c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
PKM P14618 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ATM Q13315 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
CYP3A4 P08684 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
XBP1 P17861 1/20 0.38
PAX8 Q06710 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TSHR P16473 2/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
PDE5A O76074 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840584 0.80 HTR6 (0.36) MAPTALDH1A1PKMTDP1KDM4E
SCHEMBL7826915 0.80 LMNA (0.40) MAPTALDH1A1PKMTDP1KDM4E
SCHEMBL4035593 0.80 MAPT (0.39) MAPTALDH1A1KDM4EATMNPC1
SCHEMBL1840017 0.78 MAPT (0.35) MAPTALDH1A1TDP1KDM4EATM
SCHEMBL1839990 0.77 ALDH1A1 (0.43) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL38665056 0.77 PKM (0.46) MAPTALDH1A1PKMTDP1KDM4E
SCHEMBL1842037 0.76 MAPT (0.37) MAPTALDH1A1KDM4EL3MBTL1ATM
SCHEMBL38663206 0.75 ALDH1A1 (0.47) MAPTALDH1A1PKMTDP1KDM4E
SCHEMBL3836284 0.75 LCK (0.40) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1843660 0.74 CYP1A2 (0.44) MAPTALDH1A1TDP1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-7151109-B2 Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY LLC (US) 2006-12-19 US disclosed
EP-1485384-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS Pharmacia & Upjohn Company LLC (US) 2004-12-15 EP disclosed
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY 2004-01-01 US disclosed
WO-2003078435-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators CRHR1, HTR5A, CRH MAPT 2824/4885ALDH1A1 911/4885PKM 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.